SHORT HILLS, NJ–(Marketwired – Aug 11, 2016) – Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has purchased all rights title and interest to a master advising agreement. This master agreement with HealthPartners now entitles MJTV to work with William H. Frey, II, PhD., who is an expert in intranasal delivery.
One of the largest medical research and education centers in the Midwest, HealthPartners Institute, helps transform health care in the Midwest region and across the nation. As part of HealthPartners integrated care system, the Institute uses research and education to advance the Triple Aim of improving health, experience and affordability for their members, patients and the community at large. HealthPartners Institute conducts health services, survey-based, behavioral intervention, clinical and basic science research with collaborators within HealthPartners and around the world. Our research strengths include:
- Child and maternal health
- Chronic disease/diabetes
- Clinical research
- Critical care
- Health economics
- Mental health
- Neurosciences/Alzheimer’s and Parkinson’s disease
- Oral health/dentistry
William H. Frey, II, PhD., will serve as one of MJTV’s scientific advisors and provide scientific advising services on behalf of HealthPartners Institute. MJTV will retain all right and title to all documentation and work product from this relationship. MJTV expects to add many more top scientific and medical experts in the coming weeks and months building the highest quality minds to advise and work with MJTV.
Dr. William H. Frey, II is the Founder and Co-Director of the Alzheimer’s Research Center at Regions Hospital, Professor of Pharmaceutics and faculty member in Neurology, Oral Biology and Neuroscience at the University of Minnesota and consultant to the pharmaceutical and biotechnology industry. Dr. Frey’s non-invasive intranasal method for bypassing the blood-brain barrier to rapidly delivery and target therapeutic agents to the brain along the olfactory and trigeminal neural pathways while reducing systemic exposure and unwanted side effects has captured the interest of both pharmaceutical companies and neuroscientists.
James Farinella, CEO of Michael James Enterprises, stated, “While this is new to MJTV, there has already been much time and work already invested for the future success of our company with this venture. We will be bringing in the top medical and scientific minds to the company to ensure the highest likelihood of success for MJTV and its shareholders.”
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.
Michael James Enterprises, Inc.
784 Morris Turnpike, Suite #334
Short Hills, NJ 07078